General Disclaimer: Please note that the opinions expressed here are those of the individual bloggers and do not necessarily reflect the positions of the Barts and The London School of Medicine and Dentistry nor Barts Health NHS Trust and are not meant to be interpreted as personal clinical advice.
Survey Disclaimer: No personal identifiers will be collected as part of these surveys unless otherwise stated. By completing these surveys you are consenting to the data you provide being analysed by Professor Giovannoni and his collaborators. Results of these surveys may be presented on this blog and/or submitted for publication.
Conflicts of Interest: The MS-Blog team will attempt to declare all relevant conflicts of interest (CoI) in relation to each post. We realise the success of this blog depends on us being independent, or at least being transparent, and will declare CoI on every relevant post.
We have received grant support from companies and organisations:
- The National Multiple Sclerosis Society
- The Multiple Sclerosis Society
- The Wellcome Trust
- The Medical Research Council
- Innovate UK
- And others, for which we are very grateful.
MouseDoctor has provided ad-hoc consultancies and/or been the recipient of research grants/contracts from some of the companies mentioned above He supports the concept of off label DMT use. He has received personal compensation in the past 5 years from Canbex therapeutics, InMune Bio, Japan Tabacco, Lundbeck, Merck, Novartis, Roche, Sanofi-Genzyme (last updated 26-May-2020).
MouseDoctor2 has undertaken contract research testing for some of the companies mentioned above (Last updated 26 May 2020).
Klaus Schmierer (DrK) is a principal investigator of trials sponsored by Novartis, Roche and Teva. He is also involved in trials sponsored by Biogen, Genzyme, BIAL, has received speaking honoraria from, and/or served in an advisory role for, Biogen, Novartis, Teva, Merck, Merck Inc., and support to attend meetings from Genzyme and Novartis. DrK and his group have received research grant support from Novartis, the Wellcome Trust, the National MS Society (US), the MS Society of Great Britain & Northern Ireland, the Royal College of Radiologists, and Barts Charity.
NeuroDoc Gnanapavan has served in an advisory role for Novartis and received travel support from Teva and Novartis. She has received research grant support from the National MS Society (US); Biogen, Merck, Sanofi-Genzyme Novartis and Takeda (updated 26-May-2020).
In the last 5 years, Prof G (Gavin Giovannoni) has received compensation for serving as a consultant or speaker for or has received research support from AbbVie, Aslan, Atara Bio, Biogen, BMS-Celgene, GlaxoSmithKline, GW Pharma, Janssens/J&J, Japanese Tobacco, Jazz Pharmaceuticals, LifNano, Merck & Co, Merck KGaA/EMD Serono, Novartis, Sanofi, Roche/Genentech and Teva.